- Poster presentation
- Open access
- Published:
In vitro antineoplastic activity in triple-negative breast cancer cell line and in vivo
BMC Proceedings volume 8, Article number: P22 (2014)
Background
Triple negative breast cancer (TNBC) is a heterogeneous subgroup (ER-, PR-, and HER2-) of invasive breast cancer, associated to poor prognosis, partially due to its resistance to available drugs. Therefore, it is imperative to discover new treatment options for the disease. In this context, we have synthesized and screened novel naphtoquinone-derived drugs (patent-protected), rationally designed to act through multiple pathways to avoid tumor chemoresistance.
Methods
Drugs antineoplastic efficacy (AE) was accessed in the claudin-low TNBC cell line, MDA-MB231, by cellular metabolic viability (CMV) and IC50 calculation (MTT method; GraphPad Prism version 5.1). Drugs toxicity was studied in healthy mice, following the Guideline 423 (for test of chemicals) of OECD; blood cells and tissues were analyzed by a Pathologist. Computational molecular dock studies were conducted to investigate the molecules tridimensional conformation and bounding energy to topoisomerase 2 (TOPO) and PI3K (Autodock Vina software).
Results and conclusions
We screened the AE of 43 novel drugs in MDA-MB231 (CMV≤50% with 7 drugs). Of these, the most promising drugs PIC 20 (IC50 1.38x10-5M; CMV = 10%) and PIC21 (IC50 5.00x10-5M; CMV = 30%) showed significantly higher AE than cisplatin (IC50 1.56x10-4M; CMV>90%), doxorubicin (IC50 1.76x10-4M; CMV = 62%), and paclitaxel (IC50 5.05x10-7M; CMV = 80%). None of the treated mice died, neither demonstrated symptoms of toxicity, following 14-days treatment with PIC. Indeed, there was no significant change in the animals' weight and general activity/behavior. Major organs showed no significant morphological changes, congestion, edema, necrosis, degeneration or inflammation. On the other hand, there was a 48.98% decrease in their hematocrit count. Finally, based on the crystalline structure of proteins deposited on PDB (1QZR, TOPO; 1E7U, PI3K), and PIC20 and PIC21 tridimensional structures, we concluded that the novel molecules bind to the ATP domain of the proteins with similar interaction energy (E) than the TOPO - Doxorubicin (E = -5.6) and Etoposide (E = -5.7) - or PI3K inhibitors - LY294002 (E = -9.5) and Wortmannin (E = -8.8): PIC20: E = -5.3 and -8.9; PIC21: E = -5.7 and -8.2, for TOPO and PI3K, respectively. In conclusion, we present novel and potentially safe drugs to treat TNBC, in an innovative and economically viable approach.
Acknowledgements
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de Amparo à Pesquisa do Espírito Santo (FAPES).
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Madeira, K., Cerri, M., Daltoé, R. et al. In vitro antineoplastic activity in triple-negative breast cancer cell line and in vivo. BMC Proc 8 (Suppl 4), P22 (2014). https://doi.org/10.1186/1753-6561-8-S4-P22
Published:
DOI: https://doi.org/10.1186/1753-6561-8-S4-P22